From: Jan Drew on
On May 26, 1:22�pm, Steven Bornfeld <bornfeldm...(a)dentaltwins.com>
wrote:
> john wrote:
>
> (snip)
>
>
>
> > * Taking 300 IU vitamin E per day reduces lung cancer by 61%. (Mahabir S,
> > Schendel K, Dong YQ et al. Dietary alpha-, beta-, gamma- and
> > delta-tocopherols in lung cancer risk. Int J Cancer. 2008 Sep
> > 1;123(5):1173-80.)http://www.ncbi.nlm.nih.gov/pubmed/18546288
>
> Google search terms "Vitamin E and lung cancer":
>
http://www.google.com/search?q=vitamin+e+and+lung+cancer&ie=utf-8&oe=....

And:

http://www.orthomolecular.org/resources/omns/v04n18.shtml

http://vitamins-minerals.suite101.com/article.cfm/vitamin_e_and_lung_cancer

http://www.naturalnews.com/z026242_cancer_lung_risk.html

http://www.nutraingredients.com/Research/Vitamin-E-may-slash-lung-cancer-risk-Study

From: Peter B. on
"Jan Drew" <jdrew63929(a)aol.com> wrote in message
news:efc608c9-1f01-44df-b74c-ab8e45ba3335(a)o39g2000vbd.googlegroups.com...



From: trigonometry1972 on
On May 26, 5:52 am, bigvince <vince.mirag...(a)gmail.com> wrote:
> On May 26, 1:46 am, "john" <nos...(a)bt.com> wrote:
>
> > FOR IMMEDIATE RELEASE
> > Orthomolecular Medicine News Service, May 25, 2010
>
> > Vitamin E Research Ignored by Major News Media
> > Coast-to-Coast Censorship
> > (OMNS, May 25, 2010) If you think Medline and Wikipedia are biased, take a
> > look through your newspapers and magazines. For example, have you noticed
> > how the news media are quick to publish negative allegations about vitamin
> > E, but slow to present the positive side?
>
> Great info I found this abstract particuliarly interesting
>
>    N Engl J Med. 2010 May 6;362(18):1675-85. Epub 2010 Apr 28.
> Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
>
> Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM,
> Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M,
> Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.
> Collaborators (110)
> Lavine J, Sanyal A, Abrams S, Bass N, Chalasani N, Diehl AM, Kowdley
> K, Loomba R, McCullough A, Molleston J, Murray K, Robuck P, Rosenthal
> P, Neuschwander-Tetri B, Tonascia J, Chalasani N, Sanyal A, Unalp A,
> McCullough A, Bringman D, Dasarathy S, Edwards K, Hawkins C, Liu YC,
> Rogers N, Sargent R, Diehl AM, Abdelmalek M, Gottfried M, Guy C,
> Killenberg P, Kwan S, Pan YP, Piercy D, Smith M, Chalasani N, Bhimalli
> P, Cummings OW, Klipsch A, Lee L, Molleston J, Ragozzino L,
> Vuppalanchi R, Neuschwander-Tetri BA, Derdoy J, Hoffmann J, King D,
> Siegner J, Stewart S, Thompson J, Brunt E, Lavine JE, Behling C, Clark
> L, Durelle J, Hassanein T, Petcharaporn L, Schwimmer JB, Sirlin C,
> Stein T, Bass NM, Bambha K, Ferrell LD, Filipowski D, Merriman R,
> Pabst M, Rosenthal M, Rosenthal P, Steel T, Sanyal AJ, Boyett S,
> Contos MJ, Fuchs M, Jones A, Luketic VA, Sandhu B, Sargeant C, Selph
> K, White M, Kowdley KV, Gyurkey G, Mooney J, Nelson J, Ackermann S,
> Saunders C, Stead A, Wang C, Yeh M, Kleiner D, Doo E, Everhart J,
> Hoofnagle JH, Robuck PR, Seeff L, Tonascia J, Belt P, Brancati F,
> Clark J, Colvin R, Donithan M, Green M, Isaacson M, Kim W, Miriel L,
> Sternberg A, Unalp A, Van Natta M, Vaughn I, Wilson L, Yates K.
>
> Virginia Commonwealth University, Richmond, USA. asan...(a)mcvh-vcu.edu
> Abstract
>
> BACKGROUND: Nonalcoholic steatohepatitis is a common liver disease
> that can progress to cirrhosis. Currently, there is no established
> treatment for this disease. METHODS: We randomly assigned 247 adults
> with nonalcoholic steatohepatitis and without diabetes to receive
> pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a
> dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96
> weeks. The primary outcome was an improvement in histologic features
> of nonalcoholic steatohepatitis, as assessed with the use of a
> composite of standardized scores for steatosis, lobular inflammation,
> hepatocellular ballooning, and fibrosis. Given the two planned primary
> comparisons, P values of less than 0.025 were considered to indicate
> statistical significance. RESULTS: Vitamin E therapy, as compared with
> placebo, was associated with a significantly higher rate of
> improvement in nonalcoholic steatohepatitis (43% vs. 19%, P=0.001),
> but the difference in the rate of improvement with pioglitazone as
> compared with placebo was not significant (34% and 19%, respectively;
> P=0.04). Serum alanine and aspartate aminotransferase levels were
> reduced with vitamin E and with pioglitazone, as compared with placebo
> (P<0.001 for both comparisons), and both agents were associated with
> reductions in hepatic steatosis (P=0.005 for vitamin E and P<0.001 for
> pioglitazone) and lobular inflammation (P=0.02 for vitamin E and
> P=0.004 for pioglitazone) but not with improvement in fibrosis scores
> (P=0.24 for vitamin E and P=0.12 for pioglitazone). Subjects who
> received pioglitazone gained more weight than did those who received
> vitamin E or placebo; the rates of other side effects were similar
> among the three groups. CONCLUSIONS: Vitamin E was superior to placebo
> for the treatment of nonalcoholic steatohepatitis in adults without
> diabetes. There was no benefit of pioglitazone over placebo for the
> primary outcome; however, significant benefits of pioglitazone were
> observed for some of the secondary outcomes. (ClinicalTrials.gov
> number, NCT00063622.) 2010 Massachusetts Medical Society
>
>    Certainly looks like solid science to me. Data only a pharma shill
> would dispute?

I'll suggest the ideal form would be mixed tocotrienols
or maybe very high gamma tocopherol mixed tocopherols
given its lower price by way the effects of either on insulin
response. The science for tocotrienols looks better than
than that of the high gamma tocopherol but there
are unknowns.
From: Peter B. on
<trigonometry1972(a)gmail.com> wrote in message
news:d34d8592-4cf0-42e0-b648-bc018483040c(a)g39g2000pri.googlegroups.com...
On May 26, 5:52 am, bigvince <vince.mirag...(a)gmail.com> wrote:
> On May 26, 1:46 am, "john" <nos...(a)bt.com> wrote:
>
> > FOR IMMEDIATE RELEASE
> > Orthomolecular Medicine News Service, May 25, 2010
>
> > Vitamin E Research Ignored by Major News Media
> > Coast-to-Coast Censorship
> > (OMNS, May 25, 2010) If you think Medline and Wikipedia are biased, take
> > a
> > look through your newspapers and magazines. For example, have you
> > noticed
> > how the news media are quick to publish negative allegations about
> > vitamin
> > E, but slow to present the positive side?
>
> Great info I found this abstract particuliarly interesting
>
> N Engl J Med. 2010 May 6;362(18):1675-85. Epub 2010 Apr 28.
> Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
>
> Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM,
> Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M,
> Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.
> Collaborators (110)
> Lavine J, Sanyal A, Abrams S, Bass N, Chalasani N, Diehl AM, Kowdley
> K, Loomba R, McCullough A, Molleston J, Murray K, Robuck P, Rosenthal
> P, Neuschwander-Tetri B, Tonascia J, Chalasani N, Sanyal A, Unalp A,
> McCullough A, Bringman D, Dasarathy S, Edwards K, Hawkins C, Liu YC,
> Rogers N, Sargent R, Diehl AM, Abdelmalek M, Gottfried M, Guy C,
> Killenberg P, Kwan S, Pan YP, Piercy D, Smith M, Chalasani N, Bhimalli
> P, Cummings OW, Klipsch A, Lee L, Molleston J, Ragozzino L,
> Vuppalanchi R, Neuschwander-Tetri BA, Derdoy J, Hoffmann J, King D,
> Siegner J, Stewart S, Thompson J, Brunt E, Lavine JE, Behling C, Clark
> L, Durelle J, Hassanein T, Petcharaporn L, Schwimmer JB, Sirlin C,
> Stein T, Bass NM, Bambha K, Ferrell LD, Filipowski D, Merriman R,
> Pabst M, Rosenthal M, Rosenthal P, Steel T, Sanyal AJ, Boyett S,
> Contos MJ, Fuchs M, Jones A, Luketic VA, Sandhu B, Sargeant C, Selph
> K, White M, Kowdley KV, Gyurkey G, Mooney J, Nelson J, Ackermann S,
> Saunders C, Stead A, Wang C, Yeh M, Kleiner D, Doo E, Everhart J,
> Hoofnagle JH, Robuck PR, Seeff L, Tonascia J, Belt P, Brancati F,
> Clark J, Colvin R, Donithan M, Green M, Isaacson M, Kim W, Miriel L,
> Sternberg A, Unalp A, Van Natta M, Vaughn I, Wilson L, Yates K.
>
> Virginia Commonwealth University, Richmond, USA. asan...(a)mcvh-vcu.edu
> Abstract
>
> BACKGROUND: Nonalcoholic steatohepatitis is a common liver disease
> that can progress to cirrhosis. Currently, there is no established
> treatment for this disease. METHODS: We randomly assigned 247 adults
> with nonalcoholic steatohepatitis and without diabetes to receive
> pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a
> dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96
> weeks. The primary outcome was an improvement in histologic features
> of nonalcoholic steatohepatitis, as assessed with the use of a
> composite of standardized scores for steatosis, lobular inflammation,
> hepatocellular ballooning, and fibrosis. Given the two planned primary
> comparisons, P values of less than 0.025 were considered to indicate
> statistical significance. RESULTS: Vitamin E therapy, as compared with
> placebo, was associated with a significantly higher rate of
> improvement in nonalcoholic steatohepatitis (43% vs. 19%, P=0.001),
> but the difference in the rate of improvement with pioglitazone as
> compared with placebo was not significant (34% and 19%, respectively;
> P=0.04). Serum alanine and aspartate aminotransferase levels were
> reduced with vitamin E and with pioglitazone, as compared with placebo
> (P<0.001 for both comparisons), and both agents were associated with
> reductions in hepatic steatosis (P=0.005 for vitamin E and P<0.001 for
> pioglitazone) and lobular inflammation (P=0.02 for vitamin E and
> P=0.004 for pioglitazone) but not with improvement in fibrosis scores
> (P=0.24 for vitamin E and P=0.12 for pioglitazone). Subjects who
> received pioglitazone gained more weight than did those who received
> vitamin E or placebo; the rates of other side effects were similar
> among the three groups. CONCLUSIONS: Vitamin E was superior to placebo
> for the treatment of nonalcoholic steatohepatitis in adults without
> diabetes. There was no benefit of pioglitazone over placebo for the
> primary outcome; however, significant benefits of pioglitazone were
> observed for some of the secondary outcomes. (ClinicalTrials.gov
> number, NCT00063622.) 2010 Massachusetts Medical Society
>
> Certainly looks like solid science to me. Data only a pharma shill
> would dispute?

I'll suggest the ideal form would be mixed tocotrienols
or maybe very high gamma tocopherol mixed tocopherols
given its lower price by way the effects of either on insulin
response. The science for tocotrienols looks better than
than that of the high gamma tocopherol but there
are unknowns.
===============================================
Be sure to follow Trigs ideas since vitamin E can kill, a point all of the
freaks like to ignore.


From: trigonometry1972 on
On May 28, 7:34 am, "Peter B." <.@.> wrote:
> <trigonometry1...(a)gmail.com> wrote in message
>
> news:d34d8592-4cf0-42e0-b648-bc018483040c(a)g39g2000pri.googlegroups.com...
> On May 26, 5:52 am, bigvince <vince.mirag...(a)gmail.com> wrote:
>
>
>
> > On May 26, 1:46 am, "john" <nos...(a)bt.com> wrote:
>
> > > FOR IMMEDIATE RELEASE
> > > Orthomolecular Medicine News Service, May 25, 2010
>
> > > Vitamin E Research Ignored by Major News Media
> > > Coast-to-Coast Censorship
> > > (OMNS, May 25, 2010) If you think Medline and Wikipedia are biased, take
> > > a
> > > look through your newspapers and magazines. For example, have you
> > > noticed
> > > how the news media are quick to publish negative allegations about
> > > vitamin
> > > E, but slow to present the positive side?
>
> > Great info I found this abstract particuliarly interesting
>
> > N Engl J Med. 2010 May 6;362(18):1675-85. Epub 2010 Apr 28.
> > Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
>
> > Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM,
> > Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M,
> > Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.
> > Collaborators (110)
> > Lavine J, Sanyal A, Abrams S, Bass N, Chalasani N, Diehl AM, Kowdley
> > K, Loomba R, McCullough A, Molleston J, Murray K, Robuck P, Rosenthal
> > P, Neuschwander-Tetri B, Tonascia J, Chalasani N, Sanyal A, Unalp A,
> > McCullough A, Bringman D, Dasarathy S, Edwards K, Hawkins C, Liu YC,
> > Rogers N, Sargent R, Diehl AM, Abdelmalek M, Gottfried M, Guy C,
> > Killenberg P, Kwan S, Pan YP, Piercy D, Smith M, Chalasani N, Bhimalli
> > P, Cummings OW, Klipsch A, Lee L, Molleston J, Ragozzino L,
> > Vuppalanchi R, Neuschwander-Tetri BA, Derdoy J, Hoffmann J, King D,
> > Siegner J, Stewart S, Thompson J, Brunt E, Lavine JE, Behling C, Clark
> > L, Durelle J, Hassanein T, Petcharaporn L, Schwimmer JB, Sirlin C,
> > Stein T, Bass NM, Bambha K, Ferrell LD, Filipowski D, Merriman R,
> > Pabst M, Rosenthal M, Rosenthal P, Steel T, Sanyal AJ, Boyett S,
> > Contos MJ, Fuchs M, Jones A, Luketic VA, Sandhu B, Sargeant C, Selph
> > K, White M, Kowdley KV, Gyurkey G, Mooney J, Nelson J, Ackermann S,
> > Saunders C, Stead A, Wang C, Yeh M, Kleiner D, Doo E, Everhart J,
> > Hoofnagle JH, Robuck PR, Seeff L, Tonascia J, Belt P, Brancati F,
> > Clark J, Colvin R, Donithan M, Green M, Isaacson M, Kim W, Miriel L,
> > Sternberg A, Unalp A, Van Natta M, Vaughn I, Wilson L, Yates K.
>
> > Virginia Commonwealth University, Richmond, USA. asan...(a)mcvh-vcu.edu
> > Abstract
>
> > BACKGROUND: Nonalcoholic steatohepatitis is a common liver disease
> > that can progress to cirrhosis. Currently, there is no established
> > treatment for this disease. METHODS: We randomly assigned 247 adults
> > with nonalcoholic steatohepatitis and without diabetes to receive
> > pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a
> > dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96
> > weeks. The primary outcome was an improvement in histologic features
> > of nonalcoholic steatohepatitis, as assessed with the use of a
> > composite of standardized scores for steatosis, lobular inflammation,
> > hepatocellular ballooning, and fibrosis. Given the two planned primary
> > comparisons, P values of less than 0.025 were considered to indicate
> > statistical significance. RESULTS: Vitamin E therapy, as compared with
> > placebo, was associated with a significantly higher rate of
> > improvement in nonalcoholic steatohepatitis (43% vs. 19%, P=0.001),
> > but the difference in the rate of improvement with pioglitazone as
> > compared with placebo was not significant (34% and 19%, respectively;
> > P=0.04). Serum alanine and aspartate aminotransferase levels were
> > reduced with vitamin E and with pioglitazone, as compared with placebo
> > (P<0.001 for both comparisons), and both agents were associated with
> > reductions in hepatic steatosis (P=0.005 for vitamin E and P<0.001 for
> > pioglitazone) and lobular inflammation (P=0.02 for vitamin E and
> > P=0.004 for pioglitazone) but not with improvement in fibrosis scores
> > (P=0.24 for vitamin E and P=0.12 for pioglitazone). Subjects who
> > received pioglitazone gained more weight than did those who received
> > vitamin E or placebo; the rates of other side effects were similar
> > among the three groups. CONCLUSIONS: Vitamin E was superior to placebo
> > for the treatment of nonalcoholic steatohepatitis in adults without
> > diabetes. There was no benefit of pioglitazone over placebo for the
> > primary outcome; however, significant benefits of pioglitazone were
> > observed for some of the secondary outcomes. (ClinicalTrials.gov
> > number, NCT00063622.) 2010 Massachusetts Medical Society
>
> > Certainly looks like solid science to me. Data only a pharma shill
> > would dispute?
>
> I'll suggest the ideal form would be mixed tocotrienols
> or maybe very high gamma tocopherol mixed tocopherols
> given its lower price by way the effects of either on insulin
> response. The science for tocotrienols looks better than
> than that of the high gamma tocopherol but there
> are unknowns.
> ===============================================
> Be sure to follow Trigs ideas since vitamin E can kill, a point all of the
> freaks like  to ignore.

What Peter B (was that Lizzy B?) ignores is that the
all-rac alpha tocopherol is the Peter B of the vitamin E world.